- Home
- CRSP vs SBRA Comparison
CRSP vs SBRA Comparison
Compare CRSP & SBRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRSP
- SBRA
- Stock Information
- Founded
- CRSP 2013
- SBRA 2010
- Country
- CRSP Switzerland
- SBRA United States
- Employees
- CRSP N/A
- SBRA N/A
- Industry
- CRSP Biotechnology: Biological Products (No Diagnostic Substances)
- SBRA Real Estate Investment Trusts
- Sector
- CRSP Health Care
- SBRA Real Estate
- Exchange
- CRSP Nasdaq
- SBRA Nasdaq
- Market Cap
- CRSP 4.9B
- SBRA 4.3B
- IPO Year
- CRSP 2016
- SBRA N/A
- Fundamental
- Price
- CRSP $57.68
- SBRA $17.96
- Analyst Decision
- CRSP Buy
- SBRA Buy
- Analyst Count
- CRSP 16
- SBRA 7
- Target Price
- CRSP $70.73
- SBRA $19.71
- AVG Volume (30 Days)
- CRSP 3.7M
- SBRA 2.2M
- Earning Date
- CRSP 08-04-2025
- SBRA 08-04-2025
- Dividend Yield
- CRSP N/A
- SBRA 6.62%
- EPS Growth
- CRSP N/A
- SBRA 185.79
- EPS
- CRSP N/A
- SBRA 0.60
- Revenue
- CRSP $37,675,000.00
- SBRA $720,247,000.00
- Revenue This Year
- CRSP $28.31
- SBRA $6.34
- Revenue Next Year
- CRSP $268.05
- SBRA $7.13
- P/E Ratio
- CRSP N/A
- SBRA $30.30
- Revenue Growth
- CRSP N/A
- SBRA 10.76
- 52 Week Low
- CRSP $30.04
- SBRA $15.60
- 52 Week High
- CRSP $71.13
- SBRA $20.03
- Technical
- Relative Strength Index (RSI)
- CRSP 52.32
- SBRA 43.81
- Support Level
- CRSP $61.13
- SBRA $17.89
- Resistance Level
- CRSP $69.58
- SBRA $18.55
- Average True Range (ATR)
- CRSP 3.89
- SBRA 0.33
- MACD
- CRSP -0.71
- SBRA -0.05
- Stochastic Oscillator
- CRSP 28.46
- SBRA 9.25
About CRSP CRISPR Therapeutics AG
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
About SBRA Sabra Health Care REIT Inc.
Sabra Health Care REIT Inc is a healthcare facility real estate investment trust. The company operates one segment that owns and invests in healthcare real estate. All of the company's revenue is generated in the United States. Sabra's operations consist of nursing facilities, assisted living centers, and mental health facilities.